Scholarlink

Objectives <p>Ceftolozane/tazobactam is a relevant option for treating multiresistant <i>Pseudomonas aeruginosa</i>, a major public health problem. Over a 14-month period, we studied the frequency of ceftolozane/tazobactam resistance development and mechanisms underlying resistance in <i>P. aeruginosa</i> isolates after ceftolozane/tazobactam treatment as well as alternative therapeutic options.</p> Methods <p>Antimicrobial susceptibility was assessed with the disc diffusion method and minimum inhibitory concentration (MIC) determination. Resistance genes and sequence types (ST) were determined by whole genome sequencing (WGS). The ceftolozane/tazobactam resistance mechanism was explored by cloning <i>ampC</i> into the <i>ampC-</i>deficient strain PAO1 and <i>bla</i><sub>AmpC</sub> expression experiments.</p> Results <p>Of 50 patients treated, 9 (18%) acquired one or more ceftolozane/tazobactam-resistant isolates during treatment. WGS revealed various mutations in the <i>ampC</i> gene, namely, Thr70Ile, Phe121Leu, Pro154Leu, Gly157Asp, del210-216, Glu221Lys, and the new mutation, Pro217Gln. Cloning experiments revealed that the <i>Pseudomonas-</i>derived cephalosporinase (PDC) polymorphism did not alter mutation effects, mutations did not confer the same resistance level, and those conferring the strongest resistance restored susceptibility to piperacillin, piperacillin/tazobactam and imipenem despite changes in the <i>oprD</i> gene. In clinical isolates, the resistance level conferred by the same mutations differed, indicating the involvement of other mechanisms, particularly the overproduction of AmpC, which is always present due to mutations mainly in AmpD. Finally, imipenem/relebactam, colistin, amikacin and cefiderocol could be good alternatives for treating ceftolozane/tazobactam-resistant strains.</p> Conclution <p>Ceftolozane/tazobactam resistance development was associated mainly with chromosomal mutations in the <i>ampC</i> gene but also with mutations in its regulatory genes. Knowledge about these mutations and gene polymorphisms is essential for interpreting resistance phenotypes from genomic data.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Deciphering the emergence of mutations in Pseudomonas aeruginosa after ceftolozane/tazobactam treatment and evaluating therapeutic alternatives

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月9日

查看全文
  • Léa Bientz,
  • Hugo Boijout,
  • Raoudha Grami,
  • Ulysse Guyet,
  • Marin Lahouati,
  • Melissande Hertzmann,
  • Antony Marques,
  • Audrey Toirot,
  • Sabine Aillerie,
  • Laure Coulange-Mayonnove,
  • Alexis Groppi,
  • Macha Nikolski,
  • Cécile Bébéar,
  • Véronique Dubois

摘要

Objectives

Ceftolozane/tazobactam is a relevant option for treating multiresistant Pseudomonas aeruginosa, a major public health problem. Over a 14-month period, we studied the frequency of ceftolozane/tazobactam resistance development and mechanisms underlying resistance in P. aeruginosa isolates after ceftolozane/tazobactam treatment as well as alternative therapeutic options.

Methods

Antimicrobial susceptibility was assessed with the disc diffusion method and minimum inhibitory concentration (MIC) determination. Resistance genes and sequence types (ST) were determined by whole genome sequencing (WGS). The ceftolozane/tazobactam resistance mechanism was explored by cloning ampC into the ampC-deficient strain PAO1 and blaAmpC expression experiments.

Results

Of 50 patients treated, 9 (18%) acquired one or more ceftolozane/tazobactam-resistant isolates during treatment. WGS revealed various mutations in the ampC gene, namely, Thr70Ile, Phe121Leu, Pro154Leu, Gly157Asp, del210-216, Glu221Lys, and the new mutation, Pro217Gln. Cloning experiments revealed that the Pseudomonas-derived cephalosporinase (PDC) polymorphism did not alter mutation effects, mutations did not confer the same resistance level, and those conferring the strongest resistance restored susceptibility to piperacillin, piperacillin/tazobactam and imipenem despite changes in the oprD gene. In clinical isolates, the resistance level conferred by the same mutations differed, indicating the involvement of other mechanisms, particularly the overproduction of AmpC, which is always present due to mutations mainly in AmpD. Finally, imipenem/relebactam, colistin, amikacin and cefiderocol could be good alternatives for treating ceftolozane/tazobactam-resistant strains.

Conclution

Ceftolozane/tazobactam resistance development was associated mainly with chromosomal mutations in the ampC gene but also with mutations in its regulatory genes. Knowledge about these mutations and gene polymorphisms is essential for interpreting resistance phenotypes from genomic data.